English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIn an effort five years in the making, UNC School of Medicine cell biologist Sarah Cohen, PhD, and Rockefeller University’s Ian Windham, PhD, describe the interplay between fats and proteins in brain cells and how their dysfunction contributes to the development of late-onset Alzheimer’s disease.
Tag: APOE
Brain-Belly Connection: Gut Health May Influence Likelihood of Developing Alzheimer’s
UNLV study pinpoints 10 bacterial groups associated with Alzheimer’s disease, provides new insights into the relationship between gut makeup and dementia.
Study yields clues to why Alzheimer’s disease damages certain parts of the brain
A study by researchers at Washington University School of Medicine in St. Louis yields clues to why certain parts of the brain are particularly vulnerable to Alzheimer’s damage. It comes down to the gene APOE, the greatest genetic risk factor for Alzheimer’s disease. The parts of the brain where APOE is most active are the areas that sustain the most damage, they found.
Scientists Uncover Role of Alzheimer’s-Linked APOE Gene in Glaucoma Protection and Identify Promising Treatment Strategy to Prevent Vision Loss
Scientists have demonstrated that the APOE4 gene variant, which increases risk for Alzheimer’s but decreases risk of glaucoma in humans, blocks a disease cascade that leads to the destruction of retinal ganglion cells in glaucoma. Additionally, they showed in mouse models that the death of retinal ganglion cells – the cause of vision loss in glaucoma – can be prevented by using medications to inhibit a molecule called Galectin-3, which is regulated by the APOE gene. These findings taken together emphasize the critical role of APOE in glaucoma and suggest that Galectin-3 inhibitors hold promise as a glaucoma treatment, according to the authors.
New Alzheimer’s treatment targets identified
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs with therapeutic potential.
Cholesterol-carrying protein found to help suppress immune response in pancreatic tumor microenvironment
The protein ApoE has known roles in cardiovascular disease and Alzheimer’s — new research implicates it in pancreatic cancer.
Mass Eye and Ear Receives $4 Million Gift to Accelerate Research on Genetic Links to Alzheimer’s Disease Resistance
Mass Eye and Ear has received a five-year, $4 Million gift from Good Ventures to spur Dr. Joseph F. Arboleda-Velásquez’s groundbreaking work into Alzheimer’s disease genetic resistance. This transformational gift will enable Dr. Arboleda-Velásquez to build upon the recent discovery of a genetic mutation that protected a woman who had a high familial risk for the condition and amyloid plaque deposits in her brain against early-onset Alzheimer’s.
Gene ID’d as potential therapeutic target for dementia in Parkinson’s
Researchers at Washington University School of Medicine in St. Louis have discovered that the genetic variant APOE4 – long linked to dementia – spurs the spread of harmful clumps of Parkinson’s proteins through the brain. The findings suggest that therapies that target APOE might reduce the risk of dementia for people with Parkinson’s disease.